NCT01405911View on ClinicalTrials.gov

Dose Response Finding Study of MK-0431/ONO-5435 in Japanese Subjects With Impaired Glucose Tolerance (MK-0431-105)

PHASE2CompletedINTERVENTIONAL

Enrollment

242

Participants

Timeline

Start Date

August 16, 2011

Primary Completion Date

April 9, 2012

Study Completion Date

April 9, 2012

Conditions

Glucose Intolerance

Interventions

DRUG

Placebo for Sitagliptin 25 mg

1 tablet orally once daily before breakfast for 8 weeks

DRUG

Placebo for Sitagliptin 50 mg

1 tablet orally once daily before breakfast for 8 weeks

DRUG

Sitagliptin 25 mg

1 tablet orally once daily before breakfast for 8 weeks

DRUG

Sitagliptin 50 mg

1 tablet orally once daily before breakfast for 8 weeks

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01405911 - Dose Response Finding Study of MK-0431/ONO-5435 in Japanese Subjects With Impaired Glucose Tolerance (MK-0431-105) | Biotech Hunter | Biotech Hunter